España
India
Italia
대한민국
日本
My Account
My Account
Notifications
Overview
+ New Watchlist
Benzinga Edge
Benzinga Research
Benzinga Pro
Log In
Get Benzinga Pro
Data & APIs
Events
Premarket
Boost
Advertise
Contribute
España
India
Italia
대한민국
日本
Login
Register
Our Services
News
Earnings
Guidance
Dividends
M&A
Buybacks
Legal
Interviews
Management
Offerings
IPOs
Insider Trades
Biotech/FDA
Politics
Healthcare
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Binary Options
Bonds
Futures
CME Group
Global Economics
Mining
Previews
Small-Cap
Real Estate
Penny Stocks
Digital Securities
Volatility
Options
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Whisper Index
Stock of the Day
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Prop Trading
Credit Cards
Stock Brokers
Crypto
Cannabis
Cannabis Conference
Earnings
Interviews
Deals
Regulations
Psychedelics
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Binary Options
Bonds
Futures
CME Group
Global Economics
Mining
Previews
Small-Cap
Real Estate
Penny Stocks
Digital Securities
Volatility
Options
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Whisper Index
Stock of the Day
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Prop Trading
Credit Cards
Stock Brokers
Crypto
Cannabis
Cannabis Conference
Earnings
Interviews
Deals
Regulations
Psychedelics
Research
My Stocks
Tools
Free Benzinga Pro Trial
Calendars
Analyst Ratings Calendar
Conference Call Calendar
Dividend Calendar
Earnings Calendar
Economic Calendar
FDA Calendar
Guidance Calendar
IPO Calendar
M&A Calendar
SPAC Calendar
Stock Split Calendar
Trade Ideas
Free Stock Reports
Insider Trades
Trade Idea Feed
Analyst Ratings
Unusual Options Activity
Heatmaps
Free Newsletter
Government Trades
Perfect Stock Portfolio
Easy Income Portfolio
Short Interest
Most Shorted
Largest Increase
Largest Decrease
Calculators
Margin Calculator
Forex Profit Calculator
100x Options Profit Calculator
Recent
Markets
Covidien
13 Stocks To Watch In The Healthcare Space
35 Stock Ideas Oppenheimer Analysts Love Right Now
Medtronic Expected To Report Flat Earnings Despite 55% Revenue Growth
35 Stock Ideas Oppenheimer Analysts Love Right Now
Medtronic Expected To Report Flat Earnings Despite 55% Revenue Growth
Covidien Earnings Preview: Has Merger News Shaken Expectations?
4 Top Performing Health Care Stocks With More Upside Potential
Covidien Earnings Preview: Has Merger News Shaken Expectations?
4 Top Performing Health Care Stocks With More Upside Potential
#PreMarket Primer: Monday, June 16: Rebels Seize Another Iraqi City
Earnings Expectations For The Week Of January 20: Microsoft, McDonald's, Netflix And More
Read More...
Covidien Recent News
Four Dow Components Due for a Dividend Hike (CVX, XOM, IBM, JNJ)
Earnings Expectations for the Week of July 23
Accenture, Covidien, Seagate and Other St. Patrick's Stock Picks
Seven Hot Chinese Stocks
Top Performing Health Care Stocks in January
Fifteen Health Care ETFs Trading Near 52-Week Highs
Morgan Keegan's Favorite Ideas in the Hospital Supplies Group: Baxter, Covidien, and Hill-Rom
Deutsche Bank Provides Color on Covidien, Buy
Morgan Stanley Raises PT On Covidien To $63
UPDATE: Deutsche Bank Raises PT on Covidien to $61 (COV)
Morgan Stanley Highlights From COV Analyst Day
J.P. Morgan Reiterates Overweight Rating On Covidien
Jefferies Comments On FDA Clearance From Covidien
Covidien Reports Strong Quarter, PT Raised To $56
Piper Jaffray Raises PT On Covidien To $56
Deutsche Bank On Covidien's 1Q11 Beat
Goldman On Covidien's 1Q 2011 Earnings Reported This Morning
Jefferies Raises COV Target To $56 From $52
Citigroup Raises PT On Covidien
JP Morgan Updates Model On Covidien
Morgan Keegan Reports Covidien Might Be Close to Divestiture of its Pharmaceutical Assets
Jefferies & Company Raises Covidien PT To $52
Covidien 2011 Guidance In-Line With Estimates